Literature DB >> 31341030

Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma.

Kexin Xu1, Geng Sun1, Min Li1, Hongling Chen1, Zuhao Zhang1, Xixi Qian1, Ping Li1, Lin Xu2, Wenbin Huang3, Xuerong Wang4.   

Abstract

Sulfonylurea receptor 1 (SUR1) is the regulatory subunit of ATP-sensitive potassium channels (KATP channels) and the receptor of antidiabetic drugs, such as glibenclamide, which induce insulin secretion in pancreatic β cells. However, the expression and role of SUR1 in cancer are unknown. In this study, we found that SUR1 expression was elevated in human non-small cell lung carcinoma (NSCLC) tissues and cell lines. SUR1 silencing suppressed the growth of NSCLC cells, while SUR1 overexpression promoted cell growth. Targeting SUR1 with glibenclamide suppressed cell growth, cell-cycle progression, epithelial-mesenchymal transition (EMT), and cell migration. Moreover, SUR1 directly interacted with p70S6K and upregulated p70S6K phosphorylation and activity. In addition, glibenclamide inhibited p70S6K, and overexpression of p70S6K partially reversed the growth-inhibiting effect of glibenclamide. Furthermore, glibenclamide upregulated the expression of the tumor suppressor Krüppel-like factor 4 (KLF4), and silencing KLF4 partially reversed the inhibitory effect of glibenclamide on cell growth, EMT, and migration. We found that SUR1 targeted p70S6K to downregulate KLF4 expression by enhancing DNA-methyltransferase 1-mediated methylation of the KLF4 promoter. Finally, in xenograft mouse models, SUR1 expression silencing or glibenclamide treatment inhibited the growth of A549 tumors, downregulated p70S6K activity, and upregulated KLF4 expression. These findings suggested that SUR1 expression was elevated in some NSCLC tissues and functioned as a tumor enhancer. Targeting SUR1 with glibenclamide inhibited NSCLC through downregulation of p70S6K activity and subsequent upregulation of the expression of the tumor suppressor gene KLF4 SUR1 can be developed as a new target for cancer therapy and glibenclamide has potential anticancer effects. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31341030     DOI: 10.1158/1535-7163.MCT-18-1181

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

Review 1.  Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types.

Authors:  Agnieszka Taracha-Wisniewska; Grzegorz Kotarba; Sebastian Dworkin; Tomasz Wilanowski
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

2.  Overexpressed Smurf1 is degraded in glioblastoma cells through autophagy in a p62-dependent manner.

Authors:  Da Han; Shengzhen Li; Qin Xia; Xinyi Meng; Lei Dong
Journal:  FEBS Open Bio       Date:  2021-11-15       Impact factor: 2.693

3.  The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4.

Authors:  Xiaoyan Ma; Liming Wang; Guifang Shi; Shuqing Sun
Journal:  Thorac Cancer       Date:  2022-01-30       Impact factor: 3.500

4.  Therapeutic Effect of Curcumol on Chronic Atrophic Gastritis (CAG) and Gastric Cancer Is Achieved by Downregulating SDF-1α/CXCR4/VEGF Expression.

Authors:  Xuehui Ma; Zhengbo Zhang; Xiayu Qin; Lingjing Kong; Wen Zhu; Lingzhi Xu; Xin Zhou
Journal:  J Oncol       Date:  2022-09-12       Impact factor: 4.501

5.  TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.

Authors:  María Paz Saldías; Diego Maureira; Octavio Orellana-Serradell; Ian Silva; Boris Lavanderos; Pablo Cruz; Camila Torres; Mónica Cáceres; Oscar Cerda
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.